Articles from Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026

By Quoin Pharmaceuticals, Ltd. · Via GlobeNewswire · January 20, 2026